<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844684</url>
  </required_header>
  <id_info>
    <org_study_id>2019_77</org_study_id>
    <secondary_id>2020-A03176-33</secondary_id>
    <nct_id>NCT04844684</nct_id>
  </id_info>
  <brief_title>Evaluation of Cortisol and Bile Acids Metabolism in Obese Patients</brief_title>
  <acronym>CORTABO</acronym>
  <official_title>Link Between the Metabolism of Cortisol and Bile Acids in Obese Patients Before and After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery is currently the most efficient treatment for obesity. The sustained weight&#xD;
      loss and metabolic improvement seen following Roux-en-Y gastric bypass (RYGB), is explained&#xD;
      partly by modifications in hormones including bile acids (BA). After RYGB, an increased total&#xD;
      BA pool and a reduction in hepatic cortisol exposure is observed. Hydroxysteroid 11-β&#xD;
      dehydrogenase 1 (HSD11B1), steroid 5α-reductases (SRD5A), and steroid 5β-reductases, AKR1D1&#xD;
      (also a BA metabolizing enzyme), are three enzymes involved in the metabolism of cortisol in&#xD;
      the liver and are known to participate in metabolic syndrome. Their activity has been shown&#xD;
      to be decreased after RYGB. Interestingly, the mechanisms explaining the modification of&#xD;
      hepatic cortisol exposure and the activity of theses enzymes after RYGB are unknown. In view&#xD;
      of the few data suggesting a link between cortisol metabolism and bile acids, this work aim&#xD;
      to study and characterize this link in a context of RYBP&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the variations of urinary cortisol metabolites and plasmatic total BA level before and after RYGB</measure>
    <time_frame>At 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary cortisol metabolite profile modification</measure>
    <time_frame>At 1 month after RYGP, at 1 year after RYGP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary and plasmatic BA profile modification</measure>
    <time_frame>At 1 month after RYGP, at 1 year after RYGP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the variations of cortisol metabolites and the variations of metabolic parameters 1 year after gastric bypass</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese/non-diabetic patients undergoing gastric bypass surgery</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and urine collection</intervention_name>
    <description>Blood sampling urine collections before RYGP and 1 month and 1 year after.</description>
    <arm_group_label>Obese/non-diabetic patients undergoing gastric bypass surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood (EDTA 3 mL), serum, 24 hours urine (before RYGB, 1 month and 1 year after RYGB,&#xD;
      liver tissue, adipose tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted for bariatric surgery in the department of endocrine surgery at Lille&#xD;
        University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-menopausal women&#xD;
&#xD;
          -  BMI between 35 and 45 kg/m² included&#xD;
&#xD;
          -  HbA1c &lt; 6.5%&#xD;
&#xD;
          -  Social insured&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  moderate and severe kidney insufficiency&#xD;
&#xD;
          -  hepatic insufficiency&#xD;
&#xD;
          -  known gallbladder lithiasis&#xD;
&#xD;
          -  history of cholecystectomy or cholecystectomy planned during the gastric bypass&#xD;
&#xD;
          -  history of bariatric surgery except gastric band and gastric balloon&#xD;
&#xD;
          -  history of NASH&#xD;
&#xD;
          -  history of type 1 or 2 diabetes mellitus&#xD;
&#xD;
          -  treatment interfering with the cortisol metabolism: taking oral or inhaled&#xD;
             glucocorticoids within the last 6 months&#xD;
&#xD;
          -  treatment by BA as ursodeoxycholic acid, bile acids sequester, statin, fibrate stopped&#xD;
             less than 4 weeks ago&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women obese patient</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie ESPIARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie ESPIARD, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>stephanie.espiard@chru-lille.fr</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cortisol</keyword>
  <keyword>Bile acids</keyword>
  <keyword>Obesity</keyword>
  <keyword>Bariatric surgery</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

